Drug launch in Japan to trigger $20M payment to Endo
Endo International is about to get a multimillion-dollar payday, thanks to the pending launch of Xiaflex in Japan.
On Monday, Endo said the Japan’s National Health Insurance system has placed Xiaflex — a treatment for the debilitating hand disorder Dupuytren’s contracture — on its list of approved and price-controlled prescription therapies.
Where Philadelphia ranks among the country's top life sciences clusters
As a result, Endo partner Asahi Kasei Pharma expects to commercially launch…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Dupuytren's Contracture | Health | Health Insurance | Health Management | Insurance | Pharmaceuticals